These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 3267102

  • 1. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders.
    Han ZC, Briere J, Parent D, Abgrall JF, Sensebe L.
    J Biol Regul Homeost Agents; 1988; 2(3):119-24. PubMed ID: 3267102
    [Abstract] [Full Text] [Related]

  • 2. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M.
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract] [Full Text] [Related]

  • 3. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A.
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.
    Orv Hetil; 2006 Nov 12; 147(45):2175-9. PubMed ID: 17402211
    [Abstract] [Full Text] [Related]

  • 7. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
    Hernández JM, San Miguel JF, González M, Moraleda JM, Moro MJ, Hernández J, Cuesta B, López Borrasca A.
    Med Clin (Barc); 1991 Sep 28; 97(10):369-72. PubMed ID: 1745085
    [Abstract] [Full Text] [Related]

  • 8. Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3.
    Kobayashi S, Teramura M, Hoshino S, Motoji T, Oshimi K, Mizoguchi H.
    Br J Haematol; 1993 Apr 28; 83(4):539-44. PubMed ID: 7686030
    [Abstract] [Full Text] [Related]

  • 9. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
    Sayinalp N, Cinar H, Uner A, Haznedaroğlu IC, Büyükaşik Y, Göker H, Aksu S, Ozcebe OI, Karakuş S, Kirazli S, Dündar SV.
    Clin Lab Haematol; 2004 Aug 28; 26(4):265-8. PubMed ID: 15279663
    [Abstract] [Full Text] [Related]

  • 10. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O, Loch G, Schade U, von Wasielewski R, Schlué J, Kreipe H.
    J Pathol; 2005 Apr 28; 205(5):548-57. PubMed ID: 15726648
    [Abstract] [Full Text] [Related]

  • 11. Bone marrow stromal cells in myeloproliferative disorders.
    Hirata J, Takahira H, Kaneko S, Nishimura J, Nawata H.
    Acta Haematol; 1989 Apr 28; 82(1):35-9. PubMed ID: 2505472
    [Abstract] [Full Text] [Related]

  • 12. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP, Sanchez SR, Ewton AA, Rice L, Perkins SL, Dunphy CH, Chang CC.
    Hum Pathol; 2008 Oct 28; 39(10):1454-8. PubMed ID: 18619646
    [Abstract] [Full Text] [Related]

  • 13. Endogenous erythroid colony formation in myeloproliferative diseases does not depend on T cells.
    Robak T, Hast R, Goldman JM.
    Exp Hematol; 1986 Mar 28; 14(3):197-201. PubMed ID: 3485053
    [Abstract] [Full Text] [Related]

  • 14. Hematopathologic findings in the myeloproliferative disorders.
    Dickstein JI, Vardiman JW.
    Semin Oncol; 1995 Aug 28; 22(4):355-73. PubMed ID: 7638633
    [Abstract] [Full Text] [Related]

  • 15. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders.
    Gersuk GM, Carmel R, Pattengale PK.
    Blood; 1989 Nov 15; 74(7):2330-4. PubMed ID: 2804368
    [Abstract] [Full Text] [Related]

  • 16. Differential effects of TGF-beta 1 on normal and leukemic human hematopoietic cell proliferation.
    Murohashi I, Endho K, Nishida S, Yoshida S, Jinnai I, Bessho M, Hirashima K.
    Exp Hematol; 1995 Aug 15; 23(9):970-7. PubMed ID: 7543418
    [Abstract] [Full Text] [Related]

  • 17. The effect of cyclosporin A used alone and in combination with either 2-chlorodeoxyadenosine or fludarabine on normal and chronic myelogenous leukemia progenitors in vitro.
    Korycka A, Robak T.
    Arch Immunol Ther Exp (Warsz); 2003 Aug 15; 51(1):61-7. PubMed ID: 12691305
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.